Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Impact Partnership Wealth LLC

Impact Partnership Wealth LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,950 shares of the biopharmaceutical company’s stock after purchasing an additional 194 shares during the period. Impact Partnership Wealth LLC’s holdings in Gilead Sciences were worth $1,196,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Public Sector Pension Investment Board lifted its holdings in shares of Gilead Sciences by 72.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 47,722 shares of the biopharmaceutical company’s stock valued at $3,274,000 after purchasing an additional 20,120 shares during the last quarter. Marshall Wace LLP purchased a new stake in Gilead Sciences in the second quarter valued at approximately $8,269,000. Insigneo Advisory Services LLC boosted its holdings in shares of Gilead Sciences by 1.7% in the second quarter. Insigneo Advisory Services LLC now owns 8,830 shares of the biopharmaceutical company’s stock valued at $661,000 after acquiring an additional 148 shares during the period. Point72 Asset Management L.P. grew its position in shares of Gilead Sciences by 43.2% during the second quarter. Point72 Asset Management L.P. now owns 512,125 shares of the biopharmaceutical company’s stock worth $35,137,000 after acquiring an additional 154,525 shares during the last quarter. Finally, Fred Alger Management LLC increased its holdings in shares of Gilead Sciences by 9.8% in the 2nd quarter. Fred Alger Management LLC now owns 27,357 shares of the biopharmaceutical company’s stock valued at $1,877,000 after acquiring an additional 2,442 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD opened at $92.92 on Friday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The stock has a market cap of $115.80 billion, a P/E ratio of 1,032.44, a PEG ratio of 1.31 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a 50-day moving average of $91.63 and a two-hundred day moving average of $84.63.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 in the last ninety days. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on GILD shares. Truist Financial increased their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. BMO Capital Markets upped their price objective on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.